These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28755438)

  • 21. Coexistence of malignant melanoma, Hodgkin's disease and follicular lymphoma with expression of the B-cell leukaemia/lymphoma (bcl-2) oncogene.
    Castella A; Mason N; Clarke G; Feldman A
    Histopathology; 1999 Oct; 35(4):387-8. PubMed ID: 10564396
    [No Abstract]   [Full Text] [Related]  

  • 22. Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?
    Pollio A; Tomasi A; Seidenari S; Pellacani G; Rodolfo M; Frigerio S; Maurichi A; Turchetti D; Bassoli S; Ruini C; Ponti G
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):755-7. PubMed ID: 23802662
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary cutaneous melanoma arising in agminated melanocytic nevi: CDKN2A and CDK4 mutation screening.
    Rezze GG; Leon A; Silva DC; Neves RI; Molina GC; Carraro DM; Landman G; Duprat JP
    Acta Derm Venereol; 2012 Jan; 92(1):98-9. PubMed ID: 21710107
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling.
    Orlow I; Tommasi DV; Bloom B; Ostrovnaya I; Cotignola J; Mujumdar U; Busam KJ; Jungbluth AA; Scolyer RA; Thompson JF; Armstrong BK; Berwick M; Thomas NE; Begg CB
    J Invest Dermatol; 2009 Aug; 129(8):1972-82. PubMed ID: 19282844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent inactivating RASA2 mutations in melanoma.
    Arafeh R; Qutob N; Emmanuel R; Keren-Paz A; Madore J; Elkahloun A; Wilmott JS; Gartner JJ; Di Pizio A; Winograd-Katz S; Sindiri S; Rotkopf R; Dutton-Regester K; Johansson P; Pritchard AL; Waddell N; Hill VK; Lin JC; Hevroni Y; Rosenberg SA; Khan J; Ben-Dor S; Niv MY; Ulitsky I; Mann GJ; Scolyer RA; Hayward NK; Samuels Y
    Nat Genet; 2015 Dec; 47(12):1408-10. PubMed ID: 26502337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five cases of coexistent primary ocular and cutaneous melanoma.
    Bataille V; Pinney E; Hungerford JL; Cuzick J; Bishop DT; Newton JA
    Arch Dermatol; 1993 Feb; 129(2):198-201. PubMed ID: 8434978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness.
    Fang S; Vaysse A; Brossard M; Wang Y; Deng D; Liu Q; Zhang P; Xu K; Li M; Feng R; Liu H; Dang Y; Chen W; Prieto V; Gershenwald JE; Ross MI; Matejka B; Malke J; Haydu LE; Reveille JD; Sui D; Bassett RL; Koshkina N; Avril MF; Lu M; Wei Q; Demenais F; Amos CI; Lee JE
    J Invest Dermatol; 2017 Jan; 137(1):253-257. PubMed ID: 27506587
    [No Abstract]   [Full Text] [Related]  

  • 29. The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients.
    Casula M; Budroni M; Cossu A; Ascierto PA; Mozzillo N; Canzanella S; Muggiano A; Palmieri G
    Ann Oncol; 2010 Jun; 21(6):1379-1380. PubMed ID: 20231302
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognostic signs in melanoma: state of the art.
    Lomuto M; Calabrese P; Giuliani A
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):291-300. PubMed ID: 15096138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased frequency of multiple primary melanomas in hereditary familial melanoma.
    Bork K; Bräuninger W; Nake A
    Dermatologica; 1981; 162(3):191-6. PubMed ID: 7250463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple primary cutaneous melanomas.
    Beardmore GL; Davis NC
    Arch Dermatol; 1975 May; 111(5):603-9. PubMed ID: 1130805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnosis and treatment of childhood melanoma.
    Prosdocimo T; Smith M; Polack EP
    W V Med J; 2002; 98(4):149-51. PubMed ID: 12206068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.
    Gao L; van den Hurk K; Nsengimana J; Laye JP; van den Oord JJ; Beck S; Gruis NA; Zoutman WH; van Engeland M; Newton-Bishop JA; Winnepenninckx VJ; van Doorn R
    J Invest Dermatol; 2015 Sep; 135(9):2328-2331. PubMed ID: 25918983
    [No Abstract]   [Full Text] [Related]  

  • 36. Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Gibbs DC; Ward SV; Orlow I; Cadby G; Kanetsky PA; Luo L; Busam KJ; Kricker A; Armstrong BK; Cust AE; Anton-Culver H; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Ollila DW; Begg CB; Berwick M; Thomas NE;
    Br J Dermatol; 2017 Nov; 177(5):e180-e182. PubMed ID: 28667740
    [No Abstract]   [Full Text] [Related]  

  • 37. Do not underestimate nucleotide excision repair: it predicts not only melanoma risk but also survival outcome.
    Emmert S; Kraemer KH
    J Invest Dermatol; 2013 Jul; 133(7):1713-7. PubMed ID: 23760049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival in patients with multiple primary melanomas: Systematic review and meta-analysis.
    Peek G; Olsen CM; Baade P; Youlden DR; Aitken JF; Green AC; Khosrotehrani K
    J Am Acad Dermatol; 2020 Nov; 83(5):1406-1414. PubMed ID: 32246965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
    Soares CD; Borges CF; Sena-Filho M; Almeida OP; Stelini RF; Cintra ML; Graner E; Zecchin KG; Jorge J
    Melanoma Res; 2017 Oct; 27(5):448-456. PubMed ID: 28604419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival.
    Li H; Wang Y; Liu H; Shi Q; Xu Y; Wu W; Zhu D; Amos CI; Fang S; Lee JE; Han J; Wei Q
    Int J Cancer; 2017 Mar; 140(6):1270-1279. PubMed ID: 27914105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.